A word of the CEO
A treatment soon to come
Financing Requirements
We need 250 K € to build the prototype and test it on human pancreatic cancer grafted in the mouse pancreas: this will be the “Proof of Efficiency”. Then we will look for an investor and then an industrial partner to move to the patient scale. The construction of a prototype for the man will cost 250 K €. We believe that the decisive step is the Proof of In Vivo Effectiveness, which marks the end of the research, followed by the publication of an article in a major scientific journal and conference presentations.
The development is estimated at 5 M € (3 M € for the pre-clinic and 2 M € for the clinic) and will go through an agreement with an industrialist.
All the capital raised will be used for Research & Development:
• Progressive recruitment of employees including researchers and a product manager;
• Feasibility studies in electrotechnology and nanoparticles, studies of evidence of in vivo efficacy in rodents; construction of a demonstrator and then a prototype;
• Concurrent patenting, accompanying development.
Why is the development so quick?
The consideration of mechanical signals in the formation and development of cancer is currently on the rise: the creation of an Institute of Mechanobiology in Singapore, many publications from California and New England. The partnership we have formed within a European consortium with the Faculty of Medicine of Bichat, demonstrates that the scientific community is seizing the opportunities opened by Physical Oncology.
Health products are often developed over 10 years. Because we are working under the rules of physics and not biology, because up to a certain point, we can model from the previous results, and therefore predict the following experiment, we are convinced that our development can be remarkably fast.
Which investment strategy ?
The life of our company was initially conducted on regular fundraising from investors wishing to optimize their ISF (french wealth tax). The transformation of this tax in 2017, and the progress of our work, has required that we change our funding model.
A number of public grants have become available to us in Europe and locally in France. These funds will allow us to focus on our research work for a few years.
We are now looking for Business Angels investors or companies in the healthcare sector, able to federate institutional investors around us and carry out the clinical and pre-clinical development of our innovation.
Treatment will be administered on prescription, reimbursed by health insurance systems.
One can outline a simulation (all figures excluding taxes) :
• A machine, around 2M €.
• A reimbursement of the act of passing under machine, around 1 000 €.
• An interesting price for the consumable (nanoparticles) with high margins : 3 000 €.
For France alone with 3,000 pancreas inoperable 12 M € / year.
In the USA, 16 000 patients, or 77 M $ / year.
Beyond pancreatic cancer, other applications are possible in the direction of glioblastoma, primary liver cancer, etc.
For more information, see our Executive Summary.
on road to the Proof of efficacy
A bet that is both reasonnable and generous
On the side of reason, there is a true breaking innovation protected by patent, the opening of a market without competition, a pragmatic development plan with the desired association with an industrialist.
On the side of generosity, there are patients who will find a therapeutic solution to a disease in full expansion, and participation in the emergence of a new way of understanding and caring for cancer.
We make available to potential investors the following documents : Executive Summary Balance Sheet and Income Statement 2020 Don’t hesitate to contact us for more details.
Financial news
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
CELL CONTRAINT & CANCER Centre Médical Madonuccia Av. Dr Noël Franchini 20090 Ajaccio
A word of the CEO
A treatment soon to come
Financing Requirements
We need 250 K € to build the prototype and test it on human pancreatic cancer grafted in the mouse pancreas: this will be the “Proof of Efficiency”. Then we will look for an investor and then an industrial partner to move to the patient scale. The construction of a prototype for the man will cost 250 K €. We believe that the decisive step is the Proof of In Vivo Effectiveness, which marks the end of the research, followed by the publication of an article in a major scientific journal and conference presentations.
The development is estimated at 5 M € (3 M € for the pre-clinic and 2 M € for the clinic) and will go through an agreement with an industrialist.
All the capital raised will be used for Research & Development:
• Progressive recruitment of employees including researchers and a product manager;
• Feasibility studies in electrotechnology and nanoparticles, studies of evidence of in vivo efficacy in rodents; The construction of a demonstrator and then a prototype;
• Concurrent patenting, accompanying development.
Why is the development so quick ?
Why a development so fast?
Health products are often developed over 10 years. Because we are working under the rules of physics and not biology, because up to a certain point, we can model from the previous results, and therefore predict the following experiment, we are convinced that our development can be remarkably fast.
Which investment strategy ?
The life of our company was initially conducted on regular fundraising from investors wishing to optimize their ISF (french wealth tax). The transformation of this tax in 2017, and the progress of our work, has required that we change our funding model.
A number of public grants have become available to us in Europe and locally in France. These funds will allow us to focus on our research work for a few years.
We are now looking for Business Angels investors or companies in the healthcare sector, able to federate institutional investors around us and carry out the clinical and pre-clinical development of our innovation.
Treatment will be administered on prescription, reimbursed by health insurance systems.
One can outline a simulation (all figures excluding taxes) :
• A machine, around 2M €.
• A reimbursement of the act of passing under machine, around 1 000 €.
• An interesting price for the consumable (nanoparticles) with high margins : 3 000 €.
For France alone with 3,000 pancreas inoperable 12 M € / year.
In the USA, 16 000 patients, or 77 M $ / year.
Beyond pancreatic cancer, other applications are possible in the direction of glioblastoma, primary liver cancer, etc.
For more information, see our Executive Summary.
on the road to Proof of efficacy
A bet that is both reasonable and generous
On the side of reason, there is a true breaking innovation protected by patent, the opening of a market without competition, a pragmatic development plan with the desired association with an industrialist.
On the side of generosity, there are patients who will find a therapeutic solution to a disease in full expansion, and participation in the emergence of a new way of understanding and caring for cancer.
Financial news
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
CELL CONTRAINT & CANCER Centre Médical Madonuccia Av. Dr Noël Franchini 20090 Ajaccio